Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

In-vitro Mutagenesis01:16

In-vitro Mutagenesis

14.2K
To learn more about the function of a gene, researchers can observe what happens when the gene is inactivated or “knocked out,” by creating genetically engineered knockout animals. Knockout mice have been particularly useful as models for human diseases such as cancer, Parkinson’s disease, and diabetes.
14.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

GABA signaling activation drives glioblastoma progression in female mice through myeloid-derived suppressor cells.

Nature cancer·2026
Same author

TNG917 is a Potent and Selective Inhibitor of Histone Lysine Methyltransferases EHMT1/2 that Enhances Anti-Tumor Immunity and Immunotherapy Efficacy.

Cancer research·2026
Same author

Females experience a greater benefit from surgical resection in an immune-dependent manner in a preclinical glioblastoma model.

Neuro-oncology advances·2026
Same author

Help! Male Hormones Dampen CD4+ T-cell Help in Cancer.

Cancer immunology research·2026
Same author

lncRNA in EGFR‑driven glioblastoma.

Nature cell biology·2026
Same author

Androgen loss accelerates brain tumour growth via HPA axis activation.

Nature·2026

Related Experiment Video

Updated: Aug 29, 2025

Real-Time Quantitative Measurement of Tumor Cell Migration and Invasion Following Synthetic mRNA Transfection
11:00

Real-Time Quantitative Measurement of Tumor Cell Migration and Invasion Following Synthetic mRNA Transfection

Published on: June 23, 2023

1.2K

VRK1 Is a Synthetic-Lethal Target in VRK2-Deficient Glioblastoma.

Julie A Shields1, Samuel R Meier1, Madhavi Bandi1

  • 1Tango Therapeutics, Boston, Massachusetts.

Cancer Research
|September 7, 2022
PubMed
Summary
This summary is machine-generated.

Synthetic lethality targeting vaccinia-related kinase 1 (VRK1) in glioblastoma (GBM) deficient in VRK2 shows promise. Inhibiting VRK1 kinase activity offers a potential therapeutic strategy for VRK2-methylated GBM.

More Related Videos

Genome-wide RNAi Screening to Identify Host Factors That Modulate Oncolytic Virus Therapy
08:51

Genome-wide RNAi Screening to Identify Host Factors That Modulate Oncolytic Virus Therapy

Published on: April 3, 2018

9.2K
Translational Orthotopic Models of Glioblastoma Multiforme
07:37

Translational Orthotopic Models of Glioblastoma Multiforme

Published on: February 17, 2023

3.0K

Related Experiment Videos

Last Updated: Aug 29, 2025

Real-Time Quantitative Measurement of Tumor Cell Migration and Invasion Following Synthetic mRNA Transfection
11:00

Real-Time Quantitative Measurement of Tumor Cell Migration and Invasion Following Synthetic mRNA Transfection

Published on: June 23, 2023

1.2K
Genome-wide RNAi Screening to Identify Host Factors That Modulate Oncolytic Virus Therapy
08:51

Genome-wide RNAi Screening to Identify Host Factors That Modulate Oncolytic Virus Therapy

Published on: April 3, 2018

9.2K
Translational Orthotopic Models of Glioblastoma Multiforme
07:37

Translational Orthotopic Models of Glioblastoma Multiforme

Published on: February 17, 2023

3.0K

Area of Science:

  • Cancer Therapeutics
  • Molecular Biology
  • Genetics

Background:

  • Synthetic lethality exploits genetic interactions for cancer therapy.
  • Paralog genes with redundant functions are key targets.
  • Glioblastoma (GBM) often exhibits VRK2 gene silencing via promoter methylation.

Purpose of the Study:

  • To investigate a paralog-based synthetic lethality targeting VRK1 in GBM.
  • To explore the therapeutic potential of VRK1 inhibition in VRK2-deficient GBM.

Main Methods:

  • Demonstrated synthetic lethality by targeting VRK1 in VRK2-null or VRK2-methylated GBM cells.
  • Assessed the impact of VRK1 knockdown on the downstream substrate barrier to autointegration factor (BAF).
  • Utilized glioblastoma cell line-derived xenograft and patient-derived xenograft models.

Main Results:

  • VRK1 knockdown in VRK2-deficient cells decreased BAF activity, leading to nuclear abnormalities and cell cycle arrest.
  • The synthetic-lethal interaction was dependent on VRK1 kinase activity and reversible by VRK2 expression.
  • VRK1 knockdown significantly inhibited tumor growth in xenograft models of VRK2-methylated GBM.

Conclusions:

  • A synthetic-lethal interaction exists between VRK1 and VRK2 in GBM.
  • Targeting VRK1 kinase activity is a potential therapeutic strategy for VRK2-methylated GBM.
  • VRK1 is a promising drug discovery target for this cancer type.